脂质体紫杉醇单药或联合卡培他滨治疗晚期乳腺癌42例临床观察  

Clinical study of paclitaxel liposome alone or combined with capecitabine in the treatment of 42 cases of advanced breast cancer

作　　者：李科[1] 李杨[1] 杨继岚[1] 冯志平[1] 

机构地区：[1]昆明医科大学第三附属医院云南省肿瘤研究所肿瘤化疗研究中心,云南昆明650118

出　　处：《现代肿瘤医学》2013年第1期72-74,共3页Journal of Modern Oncology

摘　　要：目的:观察脂质体紫杉醇单药或联合卡培他滨治疗晚期乳腺癌的疗效及不良反应。方法:脂质体紫杉醇135-175mg/m2,d1;卡培他滨2000mg/m2,d1-14;21d为一个治疗周期,连续治疗2-6个周期评价疗效和不良反应。结果:42例晚期乳腺癌患者中,CR 3例(7.2%),PR 19例(45.2%),总有效率52.4%。不良反应为白细胞减少、恶心、呕吐、脱发、手足综合征、血小板减少、贫血等,均为可逆性。结论:脂质体紫杉醇单药或联合卡培他滨对晚期乳腺癌疗效肯定且安全性较好,是晚期乳腺癌患者治疗的良好选择。Objective：To evaluate the efficacy and toxicity of paclitaxel liposome alone or combined with capecit- abine in the treatment of advanced breast cancer. Methods：The patients were treated with paclitaxel liposome 135 - 175mg/m^2 ,dx ,alone or combined with capecitabine 2000mg/m^2, d1-14, administered every 21 days. Results：Out of the whole group,3 cases achieved CR, 19 cases achieved PR with an ORR of 54.2%. The main toxicities were leueo- penia, nausea and vomiting, alopecia, hand - foot syndrome, thrombocytopenia, anemia. All the adverse effects were re- versible. Conclusion：The regimen of paclitaxel liposome alone or combined with capecitabine in the treatment of advanced breast cancer is effective and safe, so it can be a good regimen for advanced breast cancer.

关 键 词：乳腺癌 脂质体紫杉醇 卡培他滨 

分 类 号：R737.9[医药卫生—肿瘤]